Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotechnology company specializing in organ regeneration using patient’s own stem cells grown on biocompatible scaffolds. The company focuses on developing innovative regenerative solutions for life-threatening conditions of the esophagus, bronchus, trachea, and other tubular organs, aiming to improve patient outcomes and reduce surgical complications.
Industries
Nr. of Employees
small (1-50)
Harvard Apparatus Regenerative Technology
Holliston, Massachusetts, United States, North America
Products
Autologous cell-seeded tubular esophageal implant
A patient-specific implant composed of a hollow tubular scaffold seeded with the patient's expanded autologous mesenchymal cells, designed to bridge esophageal defects and promote in situ regeneration of the esophagus.
Autologous cell-seeded bronchial implant
A cell-seeded scaffold implant intended to repair bronchial defects and enable reattachment of main airways while preserving lung tissue.
Autologous cell-seeded tracheal implant
A tubular implant manufactured from a biocompatible scaffold and autologous cells intended to reconstruct tracheal segments and restore airway patency.
Temporary patch implant for endometrial regeneration
A temporary scaffold-based patch combined with autologous cells designed to stimulate endometrial regeneration and inhibit intrauterine adhesions following uterine procedures.
Bio-device products targeting anastomotic leak and stricture prevention
Device concepts intended to reduce anastomotic leaks and strictures after colonic resection, developed and tested in small-animal models.
Autologous cell-seeded tubular esophageal implant
A patient-specific implant composed of a hollow tubular scaffold seeded with the patient's expanded autologous mesenchymal cells, designed to bridge esophageal defects and promote in situ regeneration of the esophagus.
Autologous cell-seeded bronchial implant
A cell-seeded scaffold implant intended to repair bronchial defects and enable reattachment of main airways while preserving lung tissue.
Autologous cell-seeded tracheal implant
A tubular implant manufactured from a biocompatible scaffold and autologous cells intended to reconstruct tracheal segments and restore airway patency.
Temporary patch implant for endometrial regeneration
A temporary scaffold-based patch combined with autologous cells designed to stimulate endometrial regeneration and inhibit intrauterine adhesions following uterine procedures.
Bio-device products targeting anastomotic leak and stricture prevention
Device concepts intended to reduce anastomotic leaks and strictures after colonic resection, developed and tested in small-animal models.
Services
Clinical trial execution for autologous cell-seeded implants
Design and conduct of early-phase clinical studies evaluating safety and preliminary efficacy of autologous cell‑seeded tubular implants.
Preclinical testing and translational study support
Preclinical program design and execution in small and large animal models to evaluate implant performance, reproducibility and regeneration.
Clinical trial execution for autologous cell-seeded implants
Design and conduct of early-phase clinical studies evaluating safety and preliminary efficacy of autologous cell‑seeded tubular implants.
Preclinical testing and translational study support
Preclinical program design and execution in small and large animal models to evaluate implant performance, reproducibility and regeneration.
Expertise Areas
- Tissue engineering and regenerative medicine
- Autologous mesenchymal stem cell therapies
- Tubular organ reconstruction (esophagus, trachea, bronchus)
- Biomaterials and scaffold design
Key Technologies
- Autologous adipose-derived mesenchymal stem cell expansion
- Cell-seeded tubular implant fabrication
- Rotating bioreactor culture
- Electrospinning scaffold fabrication